It is likely that women with endometrial cancer may also benefit from metformin's antiproliferative effects, especially in obese patients who may have elevated circulating insulin and glucose levels as well as activation of the mTOR pathway in their endometrial tumors. Here, MTOR is linked to endometrium neoplasm.